Build­ing on CRISPR suc­cess, In­tel­lia inks deal for new man­u­fac­tur­ing fa­cil­i­ty in Waltham, MA

Just days af­ter In­tel­lia grant­ed the rights of some of its CRISPR-edit­ed nat­ur­al killer cells for on­col­o­gy, it’s en­ter­ing a lease agree­ment to build a 140,000 square-foot fa­cil­i­ty for its CRISPR-based ther­a­pies.

The new fa­cil­i­ty will be in Waltham, MA, and open in 2024. It will sup­port pre­clin­i­cal through com­mer­cial sup­ply in vi­vo and ex vi­vo, and af­ter it gains reg­u­la­to­ry ap­proval, will help sup­port the ex­pand­ing pipeline and com­mer­cial readi­ness by adding more ca­pac­i­ty and ca­pa­bil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER